Representatives of the Celon Pharma Neuropsychiatry Research Group took part in the 3rd Central European Biomedical Congress (CEBC) which was held on 15-18 September this year.
This is the largest scientific conference dedicated to preclinical research and biomedical sciences in our part of Europe. The theme of this year’s edition was, among others, neuropsychiatry.
During a poster session at the conference, Celon Pharma representatives presented results of preclinical research carried out under the DiSK project - "New S-ketamine therapy for treatment-resistant depression” co-financed by the National Centre for Research and Development (NCBR) under the POIR 1/1.1.1.
The conference is organised by the Institute of Pharmacology of the Polish Academy of Sciences in Cracow, the Jagiellonian University Medical College and the Polish Toxicology Society.